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ABSTRACT
CUG-BP and ETR-3 like factor (CELF) proteins are
regulators of pre-mRNA alternative splicing. We cre-
ated a series of truncation mutants to identify the
regions of CELF proteins that are required to activate
and to repress alternative splicing of different exons.
This analysis was performed in parallel on two CELF
proteins, ETR-3 (CUG-BP2, NAPOR, BRUNOL3) and
CELF4 (BRUNOL4). We identified a 20-residue region
of CELF4 required for repression or activation, in
contrast to ETR-3, for which the required residues
aremoredisperse.ForbothETR-3andCELF4,distinct
regions were required to activate splicing of two
different alternative exons, while regions required for
repression of an additional third exon overlapped
with regions required for activation. Our results sug-
gest that activation of different splicing events by
individual CELF proteins requires separable regions,
implying the nature of the protein–protein interac-
tions required for activation are target-dependent.
The finding that residues required for activation and
repression overlap suggests either that the same
region interacts with different proteins to mediate
different effects or that interactions with the same
proteins can have different effects on splicing due
to yet-to-be defined downstream events. These res-
ults provide a foundation for identifying CELF-
interacting proteins involved in activated and/or
repressed splicing.
INTRODUCTION
In higher eukaryotes, pre-mRNA alternative splicing is a
powerful and versatile regulatory mechanism by which single
genes can produce multiple mRNAs. The ﬁnal draft of the
human genome contains only 20 000–25 000 genes (1), which
encode several fold this number of proteins. This fact, plus
estimates that >60% of human genes are alternatively spliced
(2,3), underscores the importance of alternative splicing for
the diversity of the human proteome. Alternative splicing
events are regulated by trans-acting factors that bind to
regulatory cis-acting elements within pre-mRNAs (4,5).
These trans-acting factors can be expressed either in a tissue-
or in a developmental stage-speciﬁc manner or ubiquitously,
making the ratio between trans-acting factors important in the
regulation of alternative splicing (6,7).
One family of splicing regulators that controls develop-
mentally regulated and tissue-speciﬁc splicing events is the
CUG-BP and ETR-3-like factor (CELF) protein family [also
known as Bruno-like (BRUNOL) proteins] (8,9). There are six
CELF paralogs in human and mouse. CELF proteins are well-
characterized positive regulators of human and chicken car-
diac troponin T (cTNT) exon 5 alternative splicing and bind
intronic elements called muscle speciﬁc elements (MSEs)
downstream of the alternative exon (8,10–12). CELF proteins
have also been shown to regulate splicing of human insulin
receptor (IR) exon 11 (13), human muscle-speciﬁc chloride
channel (ClC-1) intron 2 (14), rat N-methyl-D-aspartate
(NMDA) receptor R1 exon 5 and exon 21 (15), alpha actinin
NM and SM exons (16), human cystic ﬁbrosis transmembrane
conductance regulator (CFTR) exon 9, human myotubularin-
related 1 (MTMR 1) exon 2.1 (17) and human polypyrimidine
tract binding protein (PTB) exon 11 (18). Interestingly, CELF
proteins can have either positive (e.g. cTNT, NMDA R1
exon 21 and PTB) or negative (e.g. IR, NMDA R1 exon 5
and ClC-1) effects on splicing of different target pre-mRNAs.
Systematic evolution of ligands by exponential enrichment
(SELEX) analysis of one CELF protein, ETR-3 (CUG-BP2,
BRUNOL3, NAPOR), identiﬁed preferred U/G-rich binding
sites that are found within introns near several of the exons
listed above. Insertion of U/G-rich motifs, representative
of the selected sequences into a cTNT minigene, made
non-responsive to ETR-3 restored responsiveness not only
to ETR-3 but also to two CELF paralogs, CUG-BP1
(BRUNOL2) and CELF4 (BRUNOL4) (17).
CELF proteins contain two N-terminal and one C-terminal
RNA recognition motif (RRM) domains separated by
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shows limited homology between CELF protein family
members and no overt homology to other proteins. To deﬁne
regions required for splicing regulation, we have performed
a functional analysis of two CELF protein family members,
CELF4 and ETR-3, which represent the two different CELF
family subgroups distinguished based on phylogenetic anal-
ysis and functional differences (8).
In this study, we identiﬁed the regions of two CELF proteins
required for splicing activation and repression. Our goals are
to identify residues required for positive and negative regula-
tion, determine whether the same residues are required for
positive regulation of different exons activated by CELF pro-
teins and to determine whether residues required for activa-
tion are separate from or overlap with residues required for
repression. The CELF protein family consists of two sub-
groups: one contains CUG-BP1 and ETR-3, which share
78% amino acids sequence identity, and the other contains
CELF3 (BRUNOL1), CELF4, CELF5 (BRUNOL5) and
CELF6 (BRUNOL6), which share 62–66% amino acid seq-
uence identity to each other and  44% identity to CUG-BP1
(8). We chose to use ETR-3 and CELF4 as representatives of
each subgroup in these analyses.
For CELF4, we had previously demonstrated that RRM-1
and -2 plus 66 amino acids within the divergent domain were
sufﬁcient to function as a splicing activator for cTNT exon 5
(19). In this study, we demonstrate that this CELF4 activation
domain (66 amino acids within divergent domain) retains the
ability to activate cTNT alternative splicing when fused to the
similar but heterologous RNA-binding domain of ETR-3. In
addition, we identiﬁed a minimal 20 residues (amino acids
239–258) within the divergent domain of CELF4 that are
required to activate cTNT exon 5. In contrast, a different
20 residues within the CELF4 activation domain (amino
acids 279–298) were required for the activation of PTB
exon 11. Meanwhile, repression of NMDA R1 exon 5 required
overlapping residues within both the regions required for the
activation of cTNT and PTB exons.
While the regions required for CELF4 activity are relatively
well deﬁned, deletion analysis of the two putative activation
domains previously identiﬁed within ETR-3 exhibited incre-
mental effects. These results suggest that the residues required
for activation by ETR-3 are spread within two separate 40- and
90-residue regions of the divergent domain. In addition, we
found signiﬁcant differences in the regions of ETR-3 required
for the activation of cTNT exon 5 and NMDA R1 exon 21
and repression of IR exon 11. Our results suggest a surprising
degree of diversity between the regions of CELF proteins that
are required to perform the same function on different pre-
mRNAs and a surprising similarity in the residues required
for opposite functions on different pre-mRNAs.
MATERIALS AND METHODS
Plasmids
CELF4 and ETR-3 deletion mutants truncated at the positions
indicated in Figures 1–6 were generated by PCR and cloned
using BamHI/XhoI into pcDNA3.1HisC(+) (Invitrogen). The
chickencTNTminigeneplasmidRTB33.51hasbeendescribed
previously (11). For the cloning of C2R.TGA, primers BXup
(GTGGTCAAGTTCGCCGACGGGGGCGGCGGGGGCA-
TCGATTGAC) and BXdn (TCGAGTCAATCGATGCCCC-
CGCCGCCCCCGTCGGCGAACTTGACCACCAGA) were
phosphorylated, annealed and cloned into BstXI/XhoI-
digested CELF4 (+48) plasmid (19). C2R.232–298 contains
amino acids 232–298 of the CELF4 divergent domain cloned
into C2R.TGA using ClaI/XhoI. For C2R.GFP67aa,
Figure 1. SplicingactivityofhumanCELF4deletionmutantson cTNTexon5
inclusion. (A) Diagram of full-length human CELF4 protein (top). Numbers
above the diagram indicate N- and C-terminal positions of the RRMs. A pre-
dominant splice variant of CELF4 was used, which lacks the N-terminal two-
thirds of RRM3 including the RNP2 sequence required for RNA binding. The
ability (+) or inability ( ) to regulate in vivo splicing of a minigene of chicken
cTNT exon 5 flanked by MSEs 1–4 is indicated. CELF4 (+48) is missing the
N-terminal 47 residues but is as active as full-length CELF4 (8). CELF4 D3.4
(48–298)andCELF4D3.5(48–258)arethe constructsusedin a previousstudy
(19). (B) Activation of chicken cTNT exon 5 inclusion by transient expression
of truncated human CELF4 proteins in QT35 quail fibroblasts. The percentage
of mRNAs that include exon 5 as determined by RT–PCR analysis was calcu-
lated as [CPM exon inclusion band/(CPM exon inclusion band + CPM exon
exclusion band)] · 100. (C) Protein extracts from plates transfected in parallel
with plates used for RT–PCR analyses were subjected to western blotting
(12.5% SDS–PAGE) using the Anti-Xpress antibody.
2770 Nucleic Acids Research, 2005, Vol. 33, No. 9C2R.ETRCD87aa and C2R.ETRND71aa, the ﬁrst 67 amino
acids of green ﬂuorescent protein (GFP), C-terminal 87 amino
acidsofETR-3divergentdomain,orN-terminal71aminoacids
of the ETR-3 divergent domain, respectively, were cloned into
the ClaI/XhoI-digested C2R.TGA vector. C2R.31aa was gen-
erated from two insertional point mutations (thymidine and
adenosine) at the ClaI cloning site of C2R.TGA during cloning
of C2R.ETRND71aa, which shifted the open reading frame of
the ETR-3 N-terminal activation domain, generating random
31 amino acids (RSILRRTKSKGASSSSSLSRCSSSTLP-
PGGT). We used C2R.31aa as a negative control for the
other chimeras. For the human NMDA R1 exon 21 minigene,
a PCR fragment that contains 111 bp of NMDA R1 alternative
exon 21 ﬂanked by 426 bp of the upstream intron and 645 of
the downstreamintron wasclonedintoRHCﬂexusingSalI and
XbaI restriction sites included in the PCR primers. The ﬁnal
NMDA R1 exon 21 minigene contains exon 1 consisting of a
51 bp fusion of RSV 50-untranslated region (50-UTR) and
skeletal troponin I (sTNI) exon 2 plus 604 bp of sTNI introns
1 and 2 upstream of the SalI site and 372 bp of sTNI intron 2
and a 289 bp fusion of sTNI exons 4 and 5 and the last exon of
skeletal a-actin downstream of the XbaI site. For the human
NMDA R1 exon 5minigene, a PCR fragmentcontaining 63 bp
of alternative exon 5 plus a BamHI restriction site at the 30 end
of the alternative exon ﬂanked by 2249 bp of the upstream
intron and 794 bp of the downstream intron was cloned into
RHCﬂex using BspEI and PpuMI restriction sites. The ﬁnal
NMDA R1 exon 5 minigene also contains the 51 bp fusion of
RSV 50-UTR and sTNI exon 2 upstream of the BspEI site and
289 bp fusion of sTNI exons 4 and 5 and the last exon of
skeletal a-actin downstream of the PpuMI site. The human
PTB exon 11 minigene was obtained from Chris Smith (Uni-
versityofCambridge,Cambridge,UK)andthe human IRexon
11 minigene was obtained from Nicolas Webster (University
of California at San Diego, La Jolla, CA). All constructs
were conﬁrmed by mapping and complete sequencing of
PCR-generated fragments, except for the NMDA R1 exon 5
genomic segment which was partially sequenced.
Cell culture and transfection
Transient transfection of plasmid DNA into quail QT35
ﬁbroblast and COS-M6 cultures and RNA extraction were
performed as described previously (8,20,21). RT–PCR ana-
lysis for RTB33.51 and NMDA R1 exon 21 minigenes was
performed as described previously (8). All results from RT–
PCR analysis were derived from at least three independent
transfections, and means (–SD) are shown. For RT–PCR ana-
lysis of the IR-F minigene, oligo(dT) (Invitrogen) was used for
reverse transcription, and IR-U (50-TAATACGACTCACTA-
TAGGGC-30) and IR-D (50-GCTGCAATAAACAAGTTC-
TGC-30) were used for PCR ampliﬁcation. For NMDA R1
exon 5 minigene RT–PCR analysis, oligo(dT) (Invitrogen)
was used for reverse transcription, and RSV5U (50-CATT-
CACCACATTGGTGTGC-30) and RTRHC (50-GGGCTTTG-
CAGCAACAGTTAAC-30) were used for PCR ampliﬁcation.
For RT–PCR analysis of the PTB minigene, CGRT (50-TAG-
TTGTACTCCAGCTT-30) was used for reverse transcription,
and CG50 (50-GGCAAAGAATTCGCCACCA-30) and PTB
dn-2 (50-CCGGACACGCTGAACTTGT-30) were used for
PCR ampliﬁcation. PCRs included a kinase-labeled oligonuc-
leotide and bands were quantiﬁed by phosphoimager analysis.
Western blot analysis of expressed proteins was performed
as previously described using AntiXpress antibody directed
against the N-terminal epitope tag encoded by the
pcDNA3.1HisC(+) vector (1:5000; Invitrogen) (22).
UV-crosslinking and immunoprecipitation of
protein expressed in vivo
C2R.232–298, C2R.TGA, C2R.ETRCD87aa, C2R.ETRND-
71aa and C2R.31aa chimera proteins expressed in vivo
were tested for RNA binding using a UV-crosslink/
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Figure 2. Splicing activity of human CELF4 chimeras on cTNT exon 5 inclu-
sion.(A)Diagramsoffull-lengthhumanCELF4proteinandchimeras.Thelight
gray box indicates a (Gly)5 linker and ClaI cloning site. Regions replacing
segments of the divergent domain are indicated by different patterns. For
CELF4.48–2525 and CELF4.48-GAPDH, the last 10 residues of CELF4.48–
268 (GAYGAYAQAL) were substituted with 10 heterologous amino acids
from CELF4.48–258 (GMFNPMAIPF) or GAPDH (VGVNGFGRIG), respec-
tively.(B)ActivationofchickencTNTexon5inclusionbytransientexpression
of truncated human CELF4 proteins in QT35 quail fibroblasts. Percentages of
mRNAsincludingexon5weredeterminedbyRT–PCRanalysisasin Figure1.
(C) Western blots were performed as in Figure 1.
Nucleic Acids Research, 2005, Vol. 33, No. 9 2771immunoprecipitation assay as described previously (22) with
the following modiﬁcations: 20 mg of protein expression
plasmid was transfected into each of the three COS-M6
150 mm plates. After 48 h, the cells were washed with
phosphate-buffered saline, then 300 ml of lysis buffer
(20 mM HEPES, 100 mM KCl, 0.05% Triton X-100, 20%
glycerol and 1 mM DTT) was added to pooled plates. Cells
were sonicated for 10 s and incubated on ice for 30 min and
centrifuged at 13 000 g for 10 min. Binding reactions were
performedwith500mgofwholecelllysatesand180000c.p.m.
Figure 3. Swapping of ETR-3 and CELF4 activation domains. (A) Diagramof CELF4 D3.4 and ETR-CELF4 chimera,in which the CELF4 activation domain was
fused to the ETR-3 N-terminal RRMs. (B) Activation of chicken cTNT exon 5 inclusion by transient expression of human CELF4 D3.4 and ETR-CELF4 chimera
in QT35 quail fibroblasts. Increasing amounts of transfected expression plasmid are indicated. The percentage of mRNAs, including exon 5, was determined by
RT–PCRanalysis.(C)ProteinextractsfromplatestransfectedinparallelwithplatesusedforRT–PCRanalyseswereseparatedonSDS–PAGEusinga10%geland
transferred onto PVDF membrane followed by western blotting using Anti-Xpress antibody. (D) Diagram of full-length CELF4 and CELF-ETR chimeras.
(E) Activation of chicken cTNT exon 5 inclusion by transient expression of chimeras in QT35 quail fibroblasts. The percentage of mRNAs, including exon 5,
wasdeterminedbyRT–PCRanalysis.(F)BindingofCELF-ETRchimeraproteinsexpressedinvivoto
32Puniformly-labeledRNAcontainingchickencTNTMSEs
2–4. COS-M6 cultures were transfected with C2R.232–298, C2R.TGA, C2R.ETRCD87aa, C2R.ETRND71aa or C2R.31aa. Total cell extracts were used for
UV-crosslinking then immunoprecipitated using AntiXpress antibody. The indicated protein samples were separated on 10% SDS–PAGE, transferred to PVDF
membraneexposedtofilmfor6daystodetectcovalentRNA–proteinadducts.FollowingtheexposuretodetecttheUV-crosslinkingsignal,membraneswereprobed
using HRP-conjugated AntiXpress antibody (1:1000). Exposure times for western blot analysis were short (10 s) and the weak signal from
32P did not make a
significant contribution. Lanes include total cell lysates (T) (10% input, e.g. 50 mg),  Ab and +Ab indicate immunoprecipitation in the absence or presence of
AntiXpress antibody, supernatants (S) and pellets (P) from immunoprecipitation.
2772 Nucleic Acids Research, 2005, Vol. 33, No. 9[
32P]GTP and [
32P]UTP-labeled RNA as described previously
(22). Western blot analysis of pelleted AntiXpress-tagged
proteins was performed using horseradish peroxidase (HRP)-
conjugated AntiXpress (Invitrogen) at 1:1000 to prevent
detection of pelleted immunoglobulin, and bands were visu-
alized with SuperSignal Chemiluminescent femto Substrate
(Pierce).
RESULTS
Identification of a minimal domain of CELF4 required
for cTNT activation
Recently, we reported that either RRM1 or RRM2 of CELF4
is necessary and sufﬁcient for binding to RNA containing the
cTNT MSE regulatory elements. Additionally, we have shown
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Figure 4. CELF4containsoverlappingactivationandrepressiondomains.(A)Diagramoffull-lengthhumanCELF4proteinanddeletionmutants.(B) Diagramsof
PTB exon 11 and NMDA R1 exon 5 minigenes.The arrows above the diagrams indicate primers used for RT–PCRanalysis. (C) Activation of human PTB exon 11
inclusion by transient expression of truncated forms of human CELF4. (D) Repression of human NMDA R1 exon 5 inclusion by transient expression of truncated
forms of human CELF4. (E) Activation of human PTB exon 11 inclusion by transient expression of finer deletion mutants of human CELF4. (F) Repression of
humanNMDAR1exon5inclusionbytransientexpressionoftruncatedandsubstitutedformsofhumanCELF4.Fortheinformationforchimeras,seethediagramin
Figure2A.TransfectionswerepreformedinCOS-M6cells.ComparablelevelsofproteinexpressionwereconfirmedbywesternblottingusingAntiXpressantibody
(data not shown).
Nucleic Acids Research, 2005, Vol. 33, No. 9 2773that RRM2 plus an additional 66 amino acids of the divergent
domain are as effective as full-length CELF4 in activating
MSE-dependent splicing in vivo (19). To further deﬁne the
speciﬁc residues of the 66 amino acids that are required for
MSE-dependent activation, we made sequential 10 amino acid
deletions from the C-terminus of the smallest truncated
CELF4 mutant that retained full activity (CELF4 D3.4, con-
taining residues 48–298) and tested their activities on the
cTNT minigene (Figure 1A). The deletion analysis demon-
strated a slight but consistent loss of activity upon deletion of
the 10 amino acids from positions 288 to 278 and a larger loss
of activity from 268 to 258 (Figure 1B). Some activity was
retained with only six residues beyond the C-terminus of
RRM2 (Figure 1B, 48–238). While steady state levels of
CELF4 D3.5 (containing residues 48–258) were consistently
reduced as shown in Figure 1C, transfections showing relat-
ively high protein expression still showed poor activation
(data not shown), indicating a loss of the intrinsic splicing
activity of CELF4.
The fact that the CELF4 deletion mutant retaining only
six residues of the divergent domain (48–238) had residual
activity suggested the possibility that the N-terminal segment
containing RRMs 1 and 2 might contribute to splicing
activation in addition to RNA binding. We created the con-
struct C2R.TGA that truncates CELF4 at position 231, the
penultimate residue of RRM2. This construct contains a linker
of ﬁve glycines [(Gly)5] and convenient restriction sites imme-
diately following RRM2, which allows cloning and testing
of regions for the activation of cTNT exon 5. The C2R.
TGA-encoded protein could not promote inclusion of cTNT
exon 5 (Figure 2B). Replacing residues 232–298 with the
N-terminus of GFP abolished the activity similar to C2R.
TGA (Figure 2B, C2RGFP67aa), indicating that the RRMs
alone are not sufﬁcient to activate cTNT exon 5. Because pre-
vious results indicate that GFP fusions with CELF proteins do
notinhibit splicing activity(23) (data notshown), we conclude
that the divergent domain of CELF4 contains the residues
that are necessaryand sufﬁcientfor the full extent ofactivation
of cTNT exon 5 inclusion. To conﬁrm that the linker does
not disrupt activation, we tested C2R.232–298, which contains
the identical region of the divergent domain as CELF4
D3.4. C2R.232–298 is nearly as active as CELF4 D3.4 in
activating cTNT exon 5 inclusion (compare Figures 1
and 2), indicating that the (Gly)5 linker does not interfere
with splicing activation.
To determine whether the reduced splicing activity resulted
from the loss of residues required for activation or from non-
speciﬁc effects of creating truncated proteins, such as protein
misfolding, reduced protein stability or translational inefﬁci-
ency, we created several constructs in which residues deﬁned
as required by the sequential deletion analysis were replaced
by substitutions. Deletion of residues 268–258 signiﬁcantly
decreased splicing activation (Figure 1); however, when these
10 residues were replaced with 10 heterologous amino acids
(residues 249–258) from CELF4 (CELF4.48-2525) or
GAPDH (CELF4.48-GAPDH), splicing activity was restored
(Figure 2B). In contrast, substitution of residues 248–268 and
238–268 with the N-terminal residues of GFP caused a loss of
activation. Taken together, these results demonstrate that resi-
dues 232–258 are required for the activation of cTNT exon 5.
The majority of this activity resides within the 20 residues
from 239 to 258. These results also demonstrate the import-
ance of substitution analysis relative to deletions alone,
because in Figure 1, 10 residues between 258 and 268 were
considered as critical residues for splicing activity, but when
we replaced them with other 10 heterologous residues, the
splicing activity was restored as shown in Figure 2.
The CELF4 activation domain is active in a
heterologous context
Previously, we reported that non-overlapping N- and
C-terminal regions of the ETR-3 divergent domain independ-
entlyserveasactivationdomains ofcTNT exon5[ETR-3 D3.4
and ETR-3 D5.7, see Figure 5, below and (19)]. Having func-
tionally deﬁned a putative activation domain of CELF4 in the
N-terminal segment of the divergent domain and two putative
activation domains within the N- and C-terminal regions of the
ETR-3 divergent domain, we next tested the ability of each of
these domains to function in a heterologous context. First, we
replaced the N-terminal ETR-3 activation domain (residues
188–258) with the CELF4 activation domain (residues 232–
298)(Figure 3A).These residuesof CELF4 retainedthe ability
to activate splicing when placed with ETR-3 RRMs 1 and 2
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Figure 5. Splicing activity of human ETR-3 deletion mutants on cTNT exon 5
inclusion. (A) Diagram of full-length human ETR-3 protein and deletion
mutants. Numbers above the diagram indicate N- and C-terminal positions
of the RRMs. Note that the isoform of ETR-3 used contains a complete
RRM3. ETR-3 D3.4, ETR-3 D3.5 and ETR-3 D5.7 are the constructs used in
a previous study (19). (B) Activation of chicken cTNT exon 5 inclusion by
transient expression of human ETR-3 full-length and truncated proteins in
QT35 quail fibroblasts. Percentage of mRNAs, including exon 5, was deter-
mined by RT–PCR analysis as in Figure 1.
2774 Nucleic Acids Research, 2005, Vol. 33, No. 9(Figure 3B). The decreased activity of the ETR-CELF4
chimera relative to CELF4 D3.4 seems to be at least partly
due to the reduced protein expression level (Figure 3C). We
conclude that the CELF4 activation domain can function in the
context of the ETR-3 RNA binding domains.
We next replaced the CELF4 divergent domain (232–298)
in C2R.232–298 with either the N-terminal (188–258, C2R.
ETRND71aa) or the C-terminal (286–372, C2R.ETRCD87aa)
activation domain of ETR-3 (Figure 3D). As a negative con-
trol, we replaced the CELF4 activation domain with a random
31amino acids(C2R.31aa)(Figure3D).Constructscontaining
either segments of the ETR-3 divergent domain showed only
very weak splicing activity (Figure 3E). We tested binding of
the chimeric proteins expressed in vivo to uniformly labeled
in vitro transcribed RNA containing cTNT MSEs 2–4 (the last
16 nt of exon 5 and the ﬁrst 149 nt of intron 5 of chicken
cTNT) which contains the binding site for ETR-3 and
CELF4 (22) (data not shown). Expression plasmids were
transiently expressed in COS-M6 cells. Whole cell lysates
were prepared after 48 h and were used in UV-crosslinking/
immunoprecipitation assays with uniformly labeled MSE
RNA as described previously (19). Binding was detected
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Figure 6. Mapping of ETR-3 residues required for the activation of NMDA exon 21 inclusion and repression of IR exon 11 inclusion. (A) Diagram of full-length
humanETR-3proteinandtheN-andC-terminaldeletionseries.(B)DiagramsofNMDAR1exon21minigeneandIRexon11minigene.PrimersusedforRT–PCR
analysis are indicated by arrows. (C) Activation of human NMDA R1 exon 21 inclusion by transient expression of full-length and truncated form of human ETR-3
assayedbyRT–PCR.(D)RepressionofhumanIR-Fexon11inclusionbytransientexpressionoffull-lengthandtruncatedformsofhumanETR-3.Transfectionswere
performed in COS-M6 cells. Comparable levels of protein expression were confirmed by western blotting using AntiXpress antibody (data not shown).
Nucleic Acids Research, 2005, Vol. 33, No. 9 2775by immunoprecipitation of protein–RNA adducts using the
AntiXpress antibody followed by autoradiography. The same
blot was then used for western blot analysis probed with HRP-
conjugated AntiXpress antibody to determine the amount of
the immunoprecipitated protein. C2R.232–298, which activ-
ates splicing (Figure 3E), binds to the MSE RNA (Figure 3F,
lane +Ab, P). C2R.TGA and C2R.31aa, which do not activate
splicing (Figures 2B and 3E, respectively), also bind to the
RNA consistent with the retention of RNA binding activity but
loss of a splicing activation domain in these proteins. Surpris-
ingly, even though C2R.ETRCD87aa and C2R.ETRND71aa
contain the same RRMsasthoseproteins thatbindto the RNA,
these two proteins showed minimal, if any, binding despite
strong protein expression. These results explain the loss of
splicing activity of C2R.ETRCD87aa and C2R.ETRND71aa.
It is important to note that neither the (Gly)5 linker alone nor
the presence of heterologous downstream sequence generally
disrupts binding since three of the ﬁve constructs retain
binding activity. This result indicates that RNA binding by
CELF4 RRMs 1 and 2 can be strongly inﬂuenced by the
downstream sequence.
Separate residues within the CELF4 divergent domain
function to activate splicing of different alternative exons
CELF proteins have been shown to regulate a number of
different alternative splicing events. Interestingly, CELF pro-
teins activate splicing of some pre-mRNA targets and repress
splicing of other targets [(13–15,18,24) and see Introduction].
We next used the deletion series of CELF4 and ETR-3 to
address two questions. First, are the residues required for the
activation of cTNT exon 5 the same as those required for the
activationofothersplicingeventsactivatedbyCELFproteins?
Second, are the residues required for repression the same or
different from those required for activation?
The residues in CELF4 required for the activation of cTNT
exon 5 were well deﬁned to a 20-residue region within the
divergent domain (239–258) (Figure 2). To determine whether
CELF4 uses the same residues to activate splicing of a dif-
ferent pre-mRNA, we tested a PTB minigene, in which exon
11 inclusion is activated by CELF4 (18). In the analysis of
the CELF4 N-terminal deletion mutants (Figure 4A), we found
that in contrast to chicken cTNT exon 5 (19), PTB exon 11
was not activated by the N-terminal CELF4 D5.1 deletion
(Figure 4C). It should be noted that CELF4 D5.1 was active
in repressing splicing of NMDA R1 exon 5 (see below) and in
activating splicing of cTNT exon 5 (19), indicating that this
protein is functional on two other pre-mRNAs. CELF4 D5.2
activated splicing of PTB exon 11 as observed previously
with cTNT exon 5 (19). CELF4 N-terminal deletion mutants
lacking the two complete N-terminal RRMs were inactive
(Figure 4A and C, D5.3–D5.7) consistent with the loss of RNA
binding reported previously (19). Analysis of C-terminal dele-
tions demonstrated an increase in activity relative to CELF4
(+48) as the C-terminus was removed. Constructs CELF4
D3.1–D3.3 demonstrated activation that was signiﬁcantly
higher than CELF4 (+48). These deletions had a similar effect
on the activation of cTNT exon 5 (19). Upon further deletion,
activation of PTB exon 11 inclusion was lost between residues
258 and 298 as was observed for cTNT. To further deﬁne the
activation domain between 258 and 298, we tested the same
constructs that we used for Figures 1 and 2. Interestingly, in
contrast to our results for cTNT exon 5, deletion of 289–298
signiﬁcantly decreased the ability of CELF4 to activate PTB
exon 11, and deletion of 279–288 completely abolished the
splicing activity (Figure 4E). We conclude that distinct
residues are required for the activation of two CELF protein
pre-mRNA targets.
Residues within CELF4 required for splicing repression
overlap with residues required for splicing activation
To determine whether the CELF4 residues required for spli-
cing repression are the same or different from those required
for splicing activation, we constructed a minigene containing
the human NMDA R1 exon 5. Exon 5 of the rat NMDA R1
gene has been shown to be repressed by ETR-3 (15). A frag-
ment of the human NMDA R1 gene consisting of the last
51 nt of exon 4 to the ﬁrst 55 nt of exon 6 was PCR ampliﬁed
and cloned into our standard minigene (Figure 4B). In this
construct,splicingofthe humanNMDAR1exon5inclusion is
repressed by ETR-3 (data not shown), although very weakly
compared with the rat exon (15). Coexpression of CELF4
(+48) with the minigene also repressed inclusion of this exon
(Figure 4D, +48). Coexpression of the NMDA R1 exon 5
minigene with the CELF4 deletion series revealed that the
regions of CELF4 required for NMDA R1 exon 5 repression
corresponded to the regions required for the activation of
cTNT exon 5 and PTB exon 11. An N-terminal deletion
that removes RRMs 1 and 2 (CELF4 D5.3) lost the ability
to repress NMDA R1 exon 5 (Figure 4D), presumably due to
the loss of RNA binding (19).
Deletions within the divergent domain between CELF4
D3.4 (position 298) and CELF4 D3.5 (position 258) deﬁned
this region as required for full repression activity. This same
region is required for the activation of cTNT exon 5 [Figure 1
and (19)] and PTB exon 11 (Figure 4C). To further deﬁne
the residues required for repression, we tested the deletion
constructs used to deﬁne the residues required for the activa-
tion of cTNT and PTB, as described above. Interestingly,
deletion of 279–288 signiﬁcantly decreased the splicing
activity and deletion of 239–248 completely abolished the
splicing activity (Figure 4F). Therefore, the set of residues
required for the activation of cTNT and the set required for
the activation of PTB contributed to full repression activity on
NMDA R1 exon 5. We conclude that residues 279–288 and
239–248 of CELF4 are required for the repression of NMDA
R1 exon 5 inclusion, residues 279–298 of CELF4 are required
for the activation of PTB exon 11, while residues 239–258 are
required for the activation of chicken cTNT exon 5.
ETR-3 residues required for cTNT exon 5 activation
are widely distributed
We have previously shown that non-overlapping N- and
C-terminal segments of ETR-3 activated inclusion of cTNT
exon 5 in a sequence-speciﬁc manner (19) (Figure 5A, ETR-3
D5.7 and ETR-3 D3.4). To further deﬁne residues within both
regions that are important for the activation of cTNT exon 5,
we sequentially deleted 10 amino acids from the termini of
the active N- and C-terminal fragments (Figure 5A). While
the ETR-3 D3.4 deletion retained most of the activity of
2776 Nucleic Acids Research, 2005, Vol. 33, No. 9full-length, sequential 10 amino acid deletions from this
N-terminal segment of ETR-3 gradually decreased the
splicing activity. Similarly, sequential deletions from ETR-3
D5.7 resulted in a gradual loss of residual activity (Figure 5B).
From this analysis, we conclude that unlike CELF4, the
residues within ETR-3 that are required for the activation
are dispersed throughout the previously deﬁned activation
domains.
Distinct domains of ETR-3 are required to activate and
repress splicing of different pre-mRNA targets
To determine whether the activation of a second pre-mRNA
target exhibited similar or different requirements compared
with cTNT (e.g. activation by non-overlapping N-terminal
and C-terminal segments), we coexpressed the ETR-3 deletion
series with a minigene containing human NMDA R1 exon 21.
At ﬁrst,we tried to use the same minigenes that we used forthe
analysisofCELF4, butneither human PTBexon11norhuman
NMDA R1 exon 5 minigenes responded strongly to ETR-3.
As mentioned above, ETR-3 did repress NMDA R1 exon 5
inclusion, but its repression activity was not as strong as that
of CELF4. These results demonstrate different speciﬁcities
of different CELF proteins to different alternative exons.
Recently, ETR-3 has been shown to activate inclusion of rat
NMDA R1 exon 21 (15) and we found that as for rat, the
human NMDA R1 exon 21 responds strongly to coexpressed
full-length ETR-3 (Figure 6C).
Sequential deletions from the N- and C-termini of ETR-3
demonstrated that the regions required for the activation of
humanNMDA R1 exon 21 differed from those requiredforthe
activation of chicken cTNT exon 5. Whereas the RNA binding
domains plus segments of the adjacent divergent domain at
either end of ETR-3 were sufﬁcient to activate cTNT exon
5 (ETR-3 D3.4 and D5.7, Figure 6A), activation of human
NMDA R1 exon 21 was nearly lost by deletion of only one
N-terminal RRM (D5.1) and was abolished by the ﬁrst deletion
that inactivates the C-terminal RRM by removing the highly
conserved RNP1 hexamer motif (D3.1) (Figure 6C). We con-
clude that unlike cTNT exon 5, activation of NMDA R1 exon
21 requires domains in both the N- and C-termini of the pro-
tein. To determine whether the complete RRM3 was required
to maintain its RNA binding activity, we tested a natural
splice variant of ETR-3 that lacks the N-terminal two-thirds
of RRM3, including the RNP2 octamer, which is required for
RNA binding activity (ETR-3 DJ). This protein activated
NMDA R1 exon 21 inclusion comparably with D5.1 and
D5.2, indicating that RNA binding activity of RRM3 is not
absolutely required and that the requirement for this domain
is indicative of another function.
To identify regions within ETR-3 that are required for
the repression of exon inclusion, we coexpressed the ETR-3
deletion series with a human IR minigene. ETR-3 repressed IR
exon 11 splicing (Figure 6D) just as has been previously
shown for the closely related CELF protein, CUG-BP1
(13). Interestingly, the deletion that removed part of RRM1
(ETR-3 D5.1) lost most of the ability to repress exon inclusion;
however, removal of an additional 40 residues (ETR-3 D5.2)
restored splicing activity. Further N-terminal deletions expec-
ted to inactivate RNA binding of the N-terminal RRMs (start-
ing with D5.3) completely abolished splicing activity. Except
for the weak residual activity of the ﬁrst C-terminal deletion,
which is predicted to inactivate RRM3 (D3.1), C-terminal
deletions lost the ability to repress inclusion of IR exon 11
(Figure 6D), despite the fact that ETR-3 D3.1–D3.4 were still
able to activate cTNT exon 5 (19). These results indicate
that the regions of ETR-3 that are sufﬁcient for the activation
of cTNT exon 5 are not individually sufﬁcient for either the
activationofNMDAR1exon21ortherepressionofIRexon11.
DISCUSSION
Definition of the minimal region required for CELF
protein splicing activity
CELF proteins regulate alternative splicing of several pre-
mRNAs by binding speciﬁc sequences within the introns adja-
cent to the alternative exons (8,13–16,22). Several alternative
splicing events are regulated either positively or negatively by
CELF proteins, depending on the pre-mRNA targets. Using a
series of sequential N- and C-terminal deletions of  40 amino
acids, we previously mapped CELF protein domains required
for the activation of chicken cTNT exon 5. These results
demonstrated that the ﬁrst 66 residues of the CELF4 diver-
gent domain (residues 233–298) serve as a putative ‘activation
domain’whenpresentwithRRMs1and2orwithRRM2alone
(19). Deletion analysis of ETR-3 identiﬁed two non-
overlapping regions of the divergent domain (189–258 with
RRMs 1 and 2; 286–404 with RRM3) that were sufﬁcient for
splicing activation of chicken cTNT exon 5 (19). In this study,
we delineated the minimal regions required for the activity of
all three regions. In addition, we tested whether the same or
different domains are required for splicing activation and
repression of different pre-mRNA targets. We note that dele-
tions caused a loss of CELF4 function, yet substitution of the
same residues demonstrated them not to be required for func-
tion (Figure 2). Results from deletion analyses should be inter-
preted with caution and substitutions are preferable to
deletions for the delineation of functional domains.
The results for CELF4 are summarized in Figure 7. CELF4
activates chicken and human cTNT exon 5, human PTB
exon 11 and represses human NMDA R1 exon 5 [(8,18)
and this study]. The same 40-residue region of the CELF4
divergent domain between constructs CELF4 D3.4 and
CELF4 D3.5 (residues 259–298) was required to activate both
cTNT exon 5 and PTB exon 11. However, ﬁner deletion/
substitution analysis demonstrated that the speciﬁc residues
required to activate the two exons were different: residues
239–258 were required for cTNT exon 5 activation (Figures 1
and 2) and residues 279–298 were required for the activation
of PTB exon 11 (Figure 4E). We also show that a protein
containing only RRMs 1 and 2 binds to at least one target
pre-mRNA (chicken cTNT) (Figure 3F, C2R.TGA). Since the
regions required for splicing regulation are not required for
RNA binding, they are most likely to function by binding other
factors required for splicing activation or repression. The ﬁnd-
ing that distinct residues of CELF proteins separated by
20 amino acids are required for the activation of different
alternative exons suggests several possibilities. One is that
the activation of different alternative exons requires interac-
tions with separate factors. Another is that the same CELF-
interacting factor activates cTNT and PTB exons by binding
Nucleic Acids Research, 2005, Vol. 33, No. 9 2777to separate regions of the CELF protein. In this case, the
two domains required for cTNT and PTB activation would
represent redundant protein–protein interaction sites. Consist-
ent with this possibility, the two regions contain methionine
and glutamine-rich motifs. It is possible that the activation of
PTB exon 11 requires more copies of a redundant interaction
domain than cTNT exon 5. Further analysis is ongoing to
identify the interacting factors required for activation.
Interestingly, the regions of the CELF4 protein required for
the repression of humanNMDA R1 exon 5 completely overlap
with those required for the activation of chicken cTNT or
human PTB (Figure 4D). The large deletion series revealed
that residues 259–298 were required for splicing repression.
Finer deletion and substitution analysis revealed that 10 resi-
dues between 279 and 288 are mainly required for repressed
splicing of NMDA R1 exon 5 by CELF4, with an additional
requirement for residues 239–248 for full activity (Figure 4F).
These results suggest that the protein–protein interactions
with CELF4 required for splicing repression are the same
as those that mediate splicing activation. Therefore, whether
the CELF complex that assembles on the pre-mRNA activates
or represses splicing could be determined by features other
than the proteins that directly interact with CELF4. For
example, where the complex assembles relative to the regu-
lated alternative exon could be determinative for repression
or activation of splicing. The CELF4 binding sites required to
regulate human PTB exon 11 and NMDA R1 exon 5 have not
yet been identiﬁed. It is also possible that different proteins
required for activation or repression interact with the same
region of CELF4, altering the effect of the regulatory complex
on recruitment or stabilization of the basal splicing machinery.
Zebraﬁsh Fox-1 (ataxin-2 binding protein 1, A2BP1) has been
demonstrated to positively regulate splicing of one pre-mRNA
and negatively regulate another. While only an N-terminal
portion of Fox-1 is required for positive regulation, a
C-terminal segment is required for positive and negative
regulation (25). These results suggest the need for different
interacting proteins to mediate different effects.
In the case of ETR-3, we were not able to further deﬁne
minimal activation domains for cTNT exon 5 splicing for
either the N- or C-terminal regions of the divergent domain,
since sequential deletions within the previously deﬁned
domain only gradually reduced splicing activity. Therefore,
the activation domains of ETR-3 appear to be spread out over
larger regions of the divergent domain and differ signiﬁcantly
from the relatively small regions within CELF4.
We showed that ETR-3 increases inclusion of the human
NMDA R1 exon 21 (Figure 6C) consistent with results repor-
ted for the rat exon (15). We also found signiﬁcant differences
in the domains requiredforthe activation ofhuman NMDA R1
exon 21 and chicken cTNT exon 5. While the non-overlapping
N- and C-terminal segments of ETR-3 containing RRMs plus
different regions of the divergent domain were capable of
sequence-speciﬁc activation of cTNT exon 5 (Figure 5) (19),
both ‘ends’ of ETR-3 were required to activate NMDA R1
exon 21. Deletions of either the N- or the C-terminal portions
of the protein inactivated its effects on NMDA R1 exon 21
(Figure 6C). That these proteins retained the ability to regulate
splicing was demonstrated previously on chicken cTNT (19).
To test another mutant lacking RRM3 binding activity, we
used a natural splice variant (ETR-3 DJ) lacking two-thirds
of RRM3, including the RNP2 motif which is required for
RNA binding. This variant activated splicing, albeit at a
reduced level, indicating that the RNA binding activity of
RRM3 is not required for full splicing activation of NMDA
R1 exon 21. These results suggest that ETR-3 requires mul-
tiple protein–protein interactions within different regions of
the divergent domains and perhaps RRM3 to promote exon
inclusion.
The N- and C-terminal ETR-3 deletions that prevented
activation of NMDA exon 21 also prevented repression of IR
exon 11 (Figure 6D). Deletion analysis of chicken ETR-3
demonstrated that in contrast to results obtained for human
ETR-3, deletion of the N-terminal quadrant of the divergent
domain or deletion of the last third of RRM3 impaired its spli-
cing activation of chicken cTNT (21). Although human and
chicken ETR-3 protein sequences are 97% identical, inclusion
of six additional amino acids (VAQMLS) in the divergent
domain of human ETR-3 at the exon 10/exon 11 boundary
andothersmalldifferencescouldberesponsibleforthesefunc-
tional discrepancies. Detailed functional comparisons of
chicken and human ETR-3 are in progress.
We compared the deﬁned CELF4 activation or repression
domain with the comparable region of other CELF family
members (Figure 7B). The comparable region within ETR-3
was also shown to activate cTNT exon inclusion (19).
Glutamine residues are most conserved among all six CELF
CELF4 RRM1 RRM2 RRM3 Divergent Domain
RRMQQMAGQMGMFNPMAIPF VAQGGYLNPMAAFAAAQMQQ
239 258 279 298
RRMQQMAGQM VAQGGYLNPM
239 248 279 288
Required for activation of cTNT exon 5
Required for activation of PTB exon 11
Required for repression of NMDA R1 exon 5
DKETRMRRM-QQMAGQMGMFNP-MA----IPFGAYGAYAQALMQQQAALMASVAQGGYLNPMAAFAAAQMQQ
QKDKEQRRLQQQLAQQMQQLNTAT-WGNLTGLGGLTPQYLALLQQATSSSNLGAFSG-IQQMAGMNALQLQN
QKDKEQKRMAQQLQQQMQQISAASVWGNLAGLNTLGPQYLALLQQTASSGNLNTLSS-LHPMGGLNAMQLQN
EKERGLRRM-QQVATQLGMFSP-IA----LQFGAYSAYTQALMQQQAALVA--AHSAYLSPMATMAAVQMQH
DKERTLRRM-QQMVGQLGILTPSLT----LPFSPYSAYAQALMQQQTTVLSTS--GSYLSPGVAFSPCHIQQ
DRERALRRM-QQMAGHLGAFHP--A---PLPLGACGAYTTAILQHQAALLA-AAQGPGLGPVAAV-AAQMQH
239 258 279 298
CELF4
ETR-3
CUG-BP
CELF3
CELF5
CELF6
Figure7.SummaryofCELF4regionsrequiredfortheactivationandrepression
of different pre-mRNA targets. (A) Deletion and substitution analyses identi-
fied 20 residues between 239 and 258 that are required for the activation of
cTNT exon 5 inclusion, 20 residues between 279 and 298 are required for the
activation of PTB exon 11 inclusion, and 10 residues between 279 and 288 as
well as 10 residues between 239 and 248 are required for full repression of
NMDA R1 exon 5 inclusion. (B) Comparison of defined activation/repression
domain among CELF family members. CELF4 residue numbers are indicated.
Conserved residues are indicated in bold font. Regions of CELF4 required for
activation of cTNT and PTB are indicated as boxes.
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residues are also conserved. It remains to be determined
whether these residues are speciﬁcally required for splicing
activation or repression. Interestingly, the C-terminal region
with the ETR-3 divergent domain that is sufﬁcient for the
activation of cTNT exon 5 does not contain obvious residue
commonalities with this N-terminal region, suggesting that at
least for cTNT, the different regions use different protein–
protein interactions to mediate splicing activation (19).
Another noticeable ﬁnding in this study is that closely
related proteins, such as CELF4 and ETR-3, can have different
pre-mRNA targets. We have shownthat CELF4 activatedPTB
exon 11 inclusion and repressed NMDA R1 exon 5 inclusion,
while neither of these minigenes were strongly regulated by
ETR-3. ETR-3 has been reported to promote rat NMDA R1
exon 21 inclusion and exon 5 skipping (15), but for human
NMDA R1 exon 5 skipping, ETR-3 regulation was weak.
Similarly, while ETR-3 strongly repressed IR-F exon 11 inclu-
sion, CELF4 had only a weak effect. It is unclear whether
these differences reﬂect differences in their RNA sequence
recognition and binding afﬁnity or accessibility to target RNA
and/or their interacting protein counterparts.
Context-dependent activities of CELF activation
domains
To determine whether the three deﬁned activation domains of
CELF4 and ETR-3 function when linked with heterologous
RNA binding domains, we placed the activation domain of
CELF4 with the N-terminal segment of ETR-3 containing
RRMs 1 and 2 (Figure 3A, ETR-CELF4 chimera) and each of
the two activation domains of ETR-3 were separately fused to
the N-terminal segment ofCELF4 containingRRMs1and2of
CELF4(Figure3D,C2R.ETRCD87aaandC2R.ETRND71aa).
Both CELF4 and ETR-3 have been shown to bind the same
MSEs ﬂanking chicken cTNT exon 5 (22) (data not shown).
These chimeras were tested for their ability to activate chicken
cTNT in vivo. The ETR-CELF4 chimera activated cTNT
exon 5 inclusion in a dose-dependent manner, although its
splicing activity was decreased compared with the same
activation domain in the context of CELF4 RRMs 1 and 2.
This could reﬂect, at least in part, the lower expression of the
ETR-CELF4 chimera protein compared with CELF4 D3.4
(Figure 3C). We conclude that the activation domain of
CELF4 functions in heterologous RNA binding domains.
In contrast, neither the N-terminal (188–258, 71 amino
acids) northe C-terminal (286–372, 87 aminoacids)activation
domains of ETR-3 functioned when they replaced the
CELF4 activation domain (232–298) (Figure 3D–F). This
loss ofactivitywasshownto bedueto theloss of RNA binding
activity (Figure 3F). This result does not necessarily mean that
the divergent domain of CELF4 is required for RNA binding,
since proteins lacking this region (C2R.TGA and C2R.31aa)
did bind to target RNA (Figure 3F). It is unclear why only
ETR-3divergentdomains prevent CELF4 RRMsfrom binding
to target RNA. It is possible that these fragments alter the
structure of the protein in a manner that is incompatible
with RNA binding.Studiesbyotherinvestigatorshave demon-
strated that non-RRM domains of CELF proteins affect the
RNA binding afﬁnity. The Xenopus ortholog of CUG-BP1,
embryo deadenylation element-binding protein (EDEN-BP),
which has 87% homology to human CUG-BP1, binds specif-
ically to the EDEN motif in the 30-UTRs of speciﬁc maternal
mRNAs. Sequence-speciﬁc binding of EDEN-BP requires the
two N-terminal RRMs and at least the ﬁrst 167 amino acids of
the divergent domain (26). Recently, Delaunay et al. (27)
showed that the Bruno (the Drosophila ortholog of CUG-
BP1) paralog Bru-3 speciﬁcally binds the EDEN element.
They also showed the divergent domain of Bru-3 is required
for speciﬁc RNA binding of the C-terminal RRM of Bru-3 to
the EDEN element.
Taken together, our results demonstrate that CELF proteins
inﬂuence splicing of diverse pre-mRNAs using distinct
regions of the protein. The activation and repression domains
deﬁned in this study will be used to identify proteins that
interact with the CELF proteins and will be a foundation to
understand the splicing mechanism of CELF protein activation
and repression of splicing activity.
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